This invention belongs to the field of pharmaceutical applications, specifically the application of esketamine
hydrochloride in the preparation of drugs for the prevention and treatment of postoperative fatigue syndrome. Through experiments, this invention demonstrates that esketamine
hydrochloride improves
fatigue symptoms in a
rat model of postoperative fatigue syndrome by enhancing exercise endurance and coordination, improving exercise speed, promoting the
recovery of autonomous exploratory behavior, and reducing
apoptosis in CA1 cells of the
hippocampus. The effects are significant within a short period, with no obvious adverse reactions, demonstrating safety and feasibility. This invention discovers a novel effect of esketamine
hydrochloride in preventing and treating postoperative fatigue syndrome, expanding its clinical application. Esketamine hydrochloride is convenient to administer and has good compliance, making it highly clinically applicable in the prevention and treatment of postoperative fatigue syndrome.